TEST:

Lunar-2

"@fireflyann I disagree. This is not a study just about how well Guardant’s LUNAR assay performs. To use anything as an INTEGRAL marker, the cart cannot be in front of the horse. Pts with IIA #CRCSM will get 6 months of chemo if assay is ➕. Won’t you want data as a pt? #GI21" (@pashtoonkasi)

"ASCO #GI21 search 8 Trials in Progress #colorectalcancer #CRCSM FRESCO2 @adasarimd MetAmp (PERSPECTIVE trial) @TaberneroJosep ECLIPSE ctDNA LUNAR-2 Test BI 754091 HER3-DXd, U3-1402 M3814 NRG-GI005 (COBRA) @VanMorrisMD Onvansertib @the_danielahn https://t.co/hhQlhdObhG" (@fireflyann)

"ICYMI: The COBRA study was activated on 12/16: NRG-GI005 Phase II/III study of #ctDNA as predictive biomarker in adjuvant chemotherapy in pts with stage IIA #coloncancer. Documents for this study are posted on @TheCTSU @TGeorgeMD @VanMorrisMD https://t.co/CzrsmwEnTu" (@NRGonc)

"The @NRGonc GI-005 COBRA study will activate across the US in December testing whether ctDNA can be used to identify “low risk” stage II colon cancer patients for clearance of MRD with chemo. Look out for this phase II/III trial and consider it for your stage II patients!" (@VanMorrisMD)